COST-EFFECTIVENESS OF SORAFENIB IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA: A SYSTEMATIC REVIEW

被引：0
|
作者：
Taheri, S. [1 ]
Motevalli, M. H. [1 ]
Peiravian, F. [1 ]
Yousefi, N. [1 ]
机构：
[1] Shahid Beheshti Univ Med Sci, Sch Pharm, Dept Pharmacoecon & Pharma Management, Tehran, Iran
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN168
引用
收藏
页码：S42 / S42
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma
    Chen, Qiuping
    Sun, Quan
    Zhang, Jing
    Li, Baixue
    Feng, Quansheng
    Liu, Jibin
    PLOS ONE, 2024, 19 (03):
  • [22] Effectiveness of sorafenib in the treatment of hepatocellular carcinoma
    Salamanca, P.
    Magalhaes, H.
    Carneiro, F.
    Marques, D.
    Faustino, C.
    Sousa, N.
    Machado, M.
    Ferreira, P.
    Raimundo, A.
    Fragoso, M.
    Lara Santos, L.
    Pereira, D.
    ANNALS OF ONCOLOGY, 2016, 27 : 52 - 52
  • [23] Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan
    Masahiro Kobayashi
    Masatoshi Kudo
    Namiki Izumi
    Shuichi Kaneko
    Mie Azuma
    Ronda Copher
    Genevieve Meier
    Janice Pan
    Mika Ishii
    Shunya Ikeda
    Journal of Gastroenterology, 2019, 54 : 558 - 570
  • [24] Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan
    Kobayashi, Masahiro
    Kudo, Masatoshi
    Izumi, Namiki
    Kaneko, Shuichi
    Azuma, Mie
    Copher, Ronda
    Meier, Genevieve
    Pan, Janice
    Ishii, Mika
    Ikeda, Shunya
    JOURNAL OF GASTROENTEROLOGY, 2019, 54 (06) : 558 - 570
  • [25] Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia
    Saiyed, Masnoon
    Byrnes, Joshua
    Srivastava, Tushar
    Scuffham, Paul
    Downes, Martin
    CLINICAL DRUG INVESTIGATION, 2020, 40 (12) : 1167 - 1176
  • [26] Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia
    Masnoon Saiyed
    Joshua Byrnes
    Tushar Srivastava
    Paul Scuffham
    Martin Downes
    Clinical Drug Investigation, 2020, 40 : 1167 - 1176
  • [27] Cost-effectiveness of measles treatment: a systematic review
    Nam Xuan Vo
    Anh Thi Van Nguyen
    Ha Thi Mai Tran
    Linh Thi Thuy Truong
    Nghi Ngoc Bao Nguyen
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2019, 69 (06) : S148 - S154
  • [28] Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review
    Zhang, Xin
    Yang, Xin-Rong
    Huang, Xiao-Wu
    Wang, Wei-Min
    Shi, Ruo-Yu
    Xu, Yang
    Wang, Zheng
    Qiu, Shuang-Jian
    Fan, Jia
    Zhou, Jian
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2012, 11 (05) : 458 - 466
  • [29] Sorafenib in treatment of patients with advanced hepatocellular carcinoma:a systematic review
    Xin Zhang
    Hepatobiliary & Pancreatic Diseases International, 2012, 11 (05) : 458 - 466
  • [30] Cost-effectiveness of sorafenib versus best supportive care in advanced hepatocellular carcinoma in Egypt
    Elsisi, Gihan Hamdy
    Nada, Yousery
    Rashad, Noha
    Carapinha, Joao
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (02) : 163 - 168
12345